Insulin-Binding Peptide Probes Provide a Novel Strategy for Pancreatic β-Cell Imaging.
Maria ErikssonSara A LitwakYan YunWilliam J StanleyPeter ThornUlf AhlgrenEsteban Nicolas GurzovPublished in: Molecular pharmaceutics (2021)
Type 1 diabetes develops in childhood and adolescence, with peak incidence in the early teenage years. There is an urgent need for an accurate method to detect insulin-producing β-cells in patients that is not affected by alterations in β-cell function. As part of our research program to design specific probes to measure β-cell mass, we recently developed a novel insulin-binding peptide probe (IBPP) for the detection of β-cells in vivo. Here, we applied our innovative method to show specific labeling of this IBPP to human and mouse fixed β-cells in pancreatic islets. Importantly, we showed staining of human and mouse islets in culture without any negative functional or cell viability impact. Moreover, the IBPP-stained mouse islets after tail vein injection in vivo, albeit with batch differences in staining efficiency. In conclusion, we provide evidence showing that the IBPP can be used for future accurate detection of β-cell mass in a variety of preclinical models of diabetes.
Keyphrases
- type diabetes
- induced apoptosis
- glycemic control
- cell cycle arrest
- single cell
- cell therapy
- endothelial cells
- endoplasmic reticulum stress
- end stage renal disease
- cardiovascular disease
- stem cells
- chronic kidney disease
- cell death
- depressive symptoms
- insulin resistance
- risk factors
- metabolic syndrome
- oxidative stress
- label free
- skeletal muscle
- induced pluripotent stem cells
- adipose tissue
- quality improvement
- quantum dots
- patient reported outcomes
- young adults
- current status
- mass spectrometry
- real time pcr
- pluripotent stem cells